Xie Pan, Liu Jun-Yan, Yan Han, Wang Zhi-Bin, Jiang Shi-Long, Li Xi, Liu Zhao-Qian
Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Institute of Clinical Pharmacology, Central South University, Changsha, China.
Front Pharmacol. 2022 Aug 11;13:950831. doi: 10.3389/fphar.2022.950831. eCollection 2022.
Discoidin, CUB, and LCCL domain-containing protein 2 () is a two-domain transmembrane protein-coding gene located on chromosome 3, the protein expressed by which acts as the membrane receptor of semaphorin and vascular endothelial growth factor during the development of axons and blood vessels. Although several research evidences at the cellular and clinical levels have associated DCBLD2 with tumorigenesis, nothing is known regarding this gene from a pan-cancer standpoint. In this study, we systematically analyzed the influence of DCBLD2 on prognosis, cancer staging, immune characteristics, and drug sensitivity in a variety of cancers based on a unified and standardized pan-cancer dataset. In addition, we performed GO enrichment analyses and KEGG analyses of -related genes and DCBLD2-binding proteins. Our results showed that DCBLD2 is a potential oncogenic, immunological as well as a prognostic biomarker in terms of pan-cancer, and is expected to contribute to the improvement of tumor prognosis and the development of targeted therapy.
含盘状结构域、CUB结构域和LCCL结构域蛋白2（DCBLD2）是一个位于3号染色体上的双结构域跨膜蛋白编码基因，该基因表达的蛋白在轴突和血管发育过程中作为信号素和血管内皮生长因子的膜受体。尽管在细胞和临床水平上有多项研究证据表明DCBLD2与肿瘤发生有关，但从泛癌角度对该基因仍知之甚少。在本研究中，我们基于统一标准化的泛癌数据集，系统分析了DCBLD2对多种癌症预后、癌症分期、免疫特征和药物敏感性的影响。此外，我们对与DCBLD2相关的基因和结合蛋白进行了基因本体（GO）富集分析和京都基因与基因组百科全书（KEGG）分析。我们的结果表明，DCBLD2在泛癌方面是一种潜在的致癌、免疫及预后生物标志物，有望为改善肿瘤预后和靶向治疗的发展做出贡献。
